Back to top

TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session

Read MoreHide Full Article

TherapeuticsMD, Inc. (TXMD - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.82 to $6.43 in the past one-month time frame.

The stock gained after an analyst at Stifel Financial provided optimistic views regarding the company's recently approved drug Imvexxy for the treatment for dyspareunia.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

TherapeuticsMD currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Drugs industry may consider ChemoCentryx, Inc. (CCXI - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is TXMD going up? Or down? Predict to see what others think:Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>
 




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ChemoCentryx, Inc. (CCXI) - free report >>

TherapeuticsMD, Inc. (TXMD) - free report >>

More from Zacks Tale of the Tape

You May Like